Picture ConsulTech GmbH RnD Credit Germany 650x80px
Organisation › Details

Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO)

Onxeo is a leading developer of orphan oncology drugs. The Company is focused on developing innovative therapeutics for rare cancers, one of the fastest growing markets in the healthcare industry with high, unmet medical needs. Onxeo’s comprehensive portfolio features a broad orphan oncology pipeline, with three independent programs in advanced clinical development, including Onxeo’s first approved orphan oncology drug, Beleodaq®. In addition, Onxeo has successfully developed and registered two non-cancer products which are currently being commercialized in the U.S. and Europe. Onxeo’s vision is to become a global leader and pioneer in oncology, with a focus on orphan or rare cancers, by developing advanced, effective, and safe therapeutics designed to improve the lives of patients. The Company is headquartered in Paris, France and has approximately 50 employees. Onxeo is listed on Euronext in Paris, France (Ticker: ONXEO, ISIN Code: FR0010095596) and NASDAQ Copenhagen, Denmark (Ticker: ONXEO). Onxeo orphan oncology products at the advanced development stage are: > Livatag® (Doxorubicin Transdrug™): Currently being evaluated in a Phase III trial (ReLive) in patients with hepatocellular carcinoma (primary liver cancer); > Validive® (Clonidine Lauriad®): Positive final results from a Phase II trial in head and neck cancer patients with severe oral mucositis; > Beleodaq® (belinostat): FDA-approved in the U.S. in 2014 under the agency’s accelerated approval program as a second-line treatment for patients with peripheral T-cell lymphoma (PTCL) and currently marketed by Onxeo’s partner in the U.S., Spectrum Pharmaceuticals; belinostat in combination with CHOP (BelCHOP) is also in development as first-line treatment for patients with PTCL. *


Period Start 2014-07-22 merged
  Group Onxeo (Group)
  Predecessor BioAlliance Pharma S.A.
Products Industry Livatag®
  Industry 2 Validive®
Persons Person Gréciet, Judith (BioAlliance Pharma 201306 CEO + France Biotech 201508 Board Member)
  Person 2 Fellmann, Nicolas (Onxeo 201606 CFO)
Region Region Paris
  Country France
  Street 49 boulevard du Général Martial Valin
  City 75015 Paris
  Tel +33-1-4558-7600
    Address record changed: 2016-07-13
Basic data Employees B: 11 to 50 (2018-12-31)
  Currency EUR
  Annual sales 6,127,000 (revenue, total, consolidated (2018) 2018-12-31)
  Profit -9,399,000 (2018-12-31)
  Cash 11,253,000 (2018-12-31)
    * Document for �About Section�: Onxeo S.A.. (2/17/16). "Press Release: Onxeo to Attend Upcoming Investor Conferences and Medical Meetings". Paris & Copenhagen.
Record changed: 2020-05-18


Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px

More documents for Onxeo (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [iito] No Content Marketing 650x80px

» top